Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    

AMA Grants MycoDART CPT Code For Its Life-Saving Test


MycoDART, Inc., developer of proprietary DNA tests, announced its second patented assay has been granted a CPT code from the American Medical Association. MycoDART-PCR for Aspergillus joins MycoDART-PCR for Candida as one of very few diagnostic devices without FDA clearance to be recognized by the AMA.

MycoDART's rapid diagnostic tests allow for the early detection of invasive fungal infections in immune-compromised patients, such as those undergoing transplants, as well as those with cancer and AIDS. Both tests have been clinically validated and are available for physicians to order from the company's affiliate, RealTime Laboratories, Inc., a Texas based clinical lab accredited by CLIA and the College of American Pathology. MycoDART has also teamed up with several prestigious university hospitals to conduct dual clinical studies.

University of Augusta, UC Davis, University of Pennsylvania, Henry Ford Health, and the University of Texas at Houston are currently at work on a study to collect samples from patients with suspected exposure to Candida. The study will compare results of MycoDART-PCR with those of blood cultures, the current gold standard. The purpose of the studies is to demonstrate efficacy in the clinical environment. Baylor Health System will lead the second study, which will employ the Aspergillus assay.

Dr. Jose Vazquez is an infectious disease specialist at the University of Augusta and is the principal investigator on Candida study. According to Dr. Vazquez, "A reliable diagnostic to quickly and accurately identify these deadly infections is long overdue. Relying on blood culture, which is a hundred year old technology that is often wrong, puts the patients at further risk."

MycoDART-PCR uses a unique process to detect very small amounts of DNA in human samples. Unlike blood cultures, which can take days to get results and are only 50% accurate, MycoDART's accuracy is as high as 95%, and results are available within hours of receiving the specimen. Early and rapid diagnosis of invasive fungal infections is key to saving lives and driving down the cost of treatment.

Immune-compromised patients face mortality within hours of being infected if not treated appropriately. Without an accurate diagnosis, doctors must treat with costly and toxic broad-spectrum antifungals. This treatment leads to lengthier hospital stays and more complications. Targeting the right organism with the most effective drug provides the best possible outcome for the patient, the hospital and the third-party payer.


Related Articles:

Recent Articles

Alexander Visits Neighborhood Health at East Side in Nashville

VIDEO of United States Senator Lamar Alexander (R-Tenn.) visiting the Neighborhood Health at East Side health center in Nashville, where he learned more about what the center is doing to provide access to health care services in urban, underserved areas of Nashville.

Read More

AMA Grants MycoDART CPT Code For Its Life-Saving Test

MycoDART, Inc., developer of proprietary DNA tests, announced its second patented assay has been granted a CPT code from the American Medical Association.

Read More

Low-level Alcohol Use Increases Miscarriage Risk

Women who consume alcohol during pregnancy -- even in small amounts -- have a 19% greater risk of miscarriage than women who don't use alcohol, according to a new study by Vanderbilt researchers.

Read More

Beating the Odds

Vanderbilt Children's Hospital researchers play key role in groundbreaking study.

Read More

Hot Topics in Healthcare Law

Never a dull moment ... the highly regulated nature of the healthcare industry keeps America's health lawyers hopping.

Read More

Vanderbilt Children's New Program Leaders, Rankings

Monroe Carell Jr. Children's Hospital at Vanderbilt has recently welcomed new leaders to oversee specialty programming and again been recognized nationally in multiple specialties.

Read More

Insuring Kids

Local experts offer insight over ongoing coverage concerns for Tennessee children

Read More

Services for Mom & Baby Expanding at TriStar Centennial

Innovative initiatives at TriStar Centennial designed to keep mom and baby safe, together.

Read More

Another Option to Address Pediatric ADHD

NeuroSigma recently received FDA clearance for the first device to treat pediatric ADHD, offering providers, patients and parents a new alternative to medication.

Read More

Back to School Reminders for Patients & Providers

Back-to-school season is here, and it's a great time to talk to patients and parents about starting off the year with healthy habits

Read More

Email Print



Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: